STOCK TITAN

[6-K] Nomura Holdings, Inc Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Smith & Nephew (NYSE:SNN) posted another solid period in its 6-K.

  • Q2 2025 revenue rose to $1.553 bn, +7.8% reported (+6.7% underlying); H1 revenue reached $2.961 bn, +4.7% reported (+5.0% underlying) despite two fewer trading days.
  • H1 trading profit climbed 11.2% to $523 m; trading margin widened 100 bps to 17.7%, while operating profit jumped 30.6% to $429 m.
  • Free cash flow surged to $244 m (H1 2024: $39 m) on 93% cash-conversion; net debt/adj. EBITDA stands at 1.8×.
  • Interim dividend increased 4.2% to 15.0¢ per share and a $500 m share-buyback was announced for H2 2025.
  • FY 2025 outlook unchanged: ~5% underlying revenue growth (5.5% reported) and 19-20% trading margin, absorbing a $15-20 m tariff hit.

Growth was broad-based: Orthopaedics +5.0% underlying, Sports Medicine & ENT +5.7%, Advanced Wound Management +10.2%. Recent product launches generated 75% of H1 growth, and the 12-Point Plan cut inventory by $69 m (-46 DSI days). Orthopaedics margin improved 230 bps; Advanced Wound margin +160 bps.

Key risks: China VBP pressure, Emerging-Markets H1 underlying −0.9%, potential 2026 Medicare changes to skin substitutes, higher trading-tax rate (19.8% vs. 17.8%) and $15-20 m tariff headwind. Nonetheless, operational gains and balance-sheet strength underpin continued cash returns.

Smith & Nephew (NYSE:SNN) ha registrato un altro periodo solido nel suo rapporto 6-K.

  • I ricavi del secondo trimestre 2025 sono aumentati a 1,553 miliardi di dollari, +7,8% riportato (+6,7% a parità di condizioni); i ricavi del primo semestre hanno raggiunto 2,961 miliardi di dollari, +4,7% riportato (+5,0% a parità di condizioni) nonostante due giorni di negoziazione in meno.
  • L'utile operativo del primo semestre è cresciuto dell'11,2% a 523 milioni di dollari; il margine operativo si è ampliato di 100 punti base al 17,7%, mentre l'utile operativo è salito del 30,6% a 429 milioni di dollari.
  • Il flusso di cassa libero è aumentato a 244 milioni di dollari (primo semestre 2024: 39 milioni) con un tasso di conversione in cassa del 93%; il rapporto debito netto/EBITDA rettificato è a 1,8×.
  • Il dividendo intermedio è stato incrementato del 4,2% a 15,0 centesimi per azione ed è stato annunciato un riacquisto di azioni per 500 milioni di dollari per il secondo semestre 2025.
  • Le previsioni per l'intero anno 2025 restano invariate: crescita dei ricavi sottostanti di circa il 5% (5,5% riportata) e margine operativo tra il 19% e il 20%, assorbendo un impatto tariffario di 15-20 milioni di dollari.

La crescita è stata diffusa: Ortopedia +5,0% a parità di condizioni, Medicina dello Sport & ORL +5,7%, Gestione Avanzata delle Ferite +10,2%. I recenti lanci di prodotto hanno generato il 75% della crescita del primo semestre, e il Piano 12-Punti ha ridotto l'inventario di 69 milioni di dollari (-46 giorni di scorte). Il margine dell'Ortopedia è migliorato di 230 punti base; quello della Gestione Avanzata delle Ferite di 160 punti base.

Rischi chiave: pressione sul prezzo di riferimento in Cina (VBP), mercati emergenti con un calo sottostante del -0,9% nel primo semestre, possibili modifiche a Medicare nel 2026 per i sostituti della pelle, aumento dell'aliquota fiscale operativa (19,8% vs. 17,8%) e impatto tariffario di 15-20 milioni di dollari. Tuttavia, i progressi operativi e la solidità del bilancio sostengono il continuo ritorno di cassa agli azionisti.

Smith & Nephew (NYSE:SNN) presentó otro período sólido en su informe 6-K.

  • Los ingresos del segundo trimestre de 2025 aumentaron a 1.553 millones de dólares, +7,8% reportado (+6,7% subyacente); los ingresos del primer semestre alcanzaron 2.961 millones de dólares, +4,7% reportado (+5,0% subyacente) a pesar de dos días de negociación menos.
  • El beneficio operativo del primer semestre creció un 11,2% hasta 523 millones; el margen operativo se amplió 100 puntos básicos hasta el 17,7%, mientras que el beneficio operativo aumentó un 30,6% hasta 429 millones.
  • El flujo de caja libre subió a 244 millones (primer semestre 2024: 39 millones) con una conversión de caja del 93%; la deuda neta/EBITDA ajustado se sitúa en 1,8×.
  • El dividendo intermedio aumentó un 4,2% hasta 15,0 centavos por acción y se anunció una recompra de acciones de 500 millones de dólares para el segundo semestre de 2025.
  • Las perspectivas para todo el año 2025 permanecen sin cambios: crecimiento subyacente de ingresos de alrededor del 5% (5,5% reportado) y margen operativo del 19-20%, absorbiendo un impacto arancelario de 15-20 millones de dólares.

El crecimiento fue generalizado: Ortopedia +5,0% subyacente, Medicina Deportiva & ORL +5,7%, Gestión Avanzada de Heridas +10,2%. Los recientes lanzamientos de productos generaron el 75% del crecimiento del primer semestre, y el Plan de 12 Puntos redujo el inventario en 69 millones de dólares (-46 días de inventario). El margen de Ortopedia mejoró 230 puntos básicos; el margen de Gestión Avanzada de Heridas +160 puntos básicos.

Riesgos clave: presión VBP en China, mercados emergentes con un descenso subyacente del -0,9% en el primer semestre, posibles cambios en Medicare en 2026 para sustitutos de piel, mayor tasa impositiva operativa (19,8% vs. 17,8%) e impacto arancelario de 15-20 millones de dólares. No obstante, las mejoras operativas y la fortaleza del balance respaldan la continuidad en la devolución de efectivo a los accionistas.

Smith & Nephew (NYSE:SNN)는 6-K 보고서에서 또 한 번 견고한 실적을 발표했습니다.

  • 2025년 2분기 매출은 15억 5,300만 달러로 전년 대비 7.8% 증가(기저 효과 제외 6.7% 증가); 상반기 매출은 29억 6,100만 달러로 4.7% 증가(기저 효과 제외 5.0% 증가)했으며, 거래일이 2일 줄었음에도 불구하고 성장했습니다.
  • 상반기 영업이익은 5억 2,300만 달러로 11.2% 증가했고, 영업이익률은 100bp 확대되어 17.7%를 기록했으며, 영업이익은 4억 2,900만 달러로 30.6% 급증했습니다.
  • 자유현금흐름은 2억 4,400만 달러로 급증했으며(2024년 상반기: 3,900만 달러), 현금 전환율은 93%에 달했습니다; 순부채/조정 EBITDA 비율은 1.8배입니다.
  • 중간배당금은 주당 15.0센트로 4.2% 인상되었으며, 2025년 하반기에는 5억 달러 규모의 자사주 매입이 발표되었습니다.
  • 2025년 연간 전망은 변함없으며, 기저 효과 제외 매출 성장 약 5%(보고 기준 5.5%), 19-20%의 영업이익률을 예상하며, 1,500만~2,000만 달러의 관세 영향이 반영됩니다.

성장은 전 부문에 걸쳐 나타났습니다: 정형외과 +5.0% 기저 효과 제외, 스포츠 의학 및 이비인후과 +5.7%, 첨단 상처 관리 +10.2%. 최근 출시된 제품들이 상반기 성장의 75%를 차지했으며, 12포인트 계획으로 재고가 6,900만 달러(-46일 재고일수) 감소했습니다. 정형외과 마진은 230bp 개선되었고, 첨단 상처 관리 마진은 160bp 상승했습니다.

주요 위험요인: 중국의 VBP 압력, 신흥 시장 상반기 기저 효과 제외 -0.9%, 2026년 피부 대체재 관련 Medicare 변경 가능성, 영업세율 상승(19.8% vs. 17.8%), 1,500만~2,000만 달러 관세 부담. 그럼에도 불구하고 운영 성과와 재무 건전성이 지속적인 현금 환원 기반을 뒷받침합니다.

Smith & Nephew (NYSE:SNN) a publié une nouvelle période solide dans son rapport 6-K.

  • Le chiffre d'affaires du deuxième trimestre 2025 a augmenté pour atteindre 1,553 milliard de dollars, +7,8% en données publiées (+6,7% en données sous-jacentes) ; le chiffre d'affaires du premier semestre a atteint 2,961 milliards de dollars, +4,7% en données publiées (+5,0% en données sous-jacentes) malgré deux jours de bourse en moins.
  • Le résultat opérationnel courant du premier semestre a progressé de 11,2% à 523 millions de dollars ; la marge opérationnelle s'est élargie de 100 points de base à 17,7%, tandis que le résultat opérationnel a bondi de 30,6% à 429 millions de dollars.
  • La trésorerie nette disponible a fortement augmenté à 244 millions de dollars (S1 2024 : 39 millions) avec un taux de conversion de trésorerie de 93 % ; la dette nette/EBITDA ajusté s'établit à 1,8×.
  • Le dividende intérimaire a été augmenté de 4,2 % à 15,0 cents par action et un rachat d'actions de 500 millions de dollars a été annoncé pour le second semestre 2025.
  • Les perspectives pour l'exercice 2025 restent inchangées : croissance sous-jacente du chiffre d'affaires d'environ 5 % (5,5 % en données publiées) et marge opérationnelle de 19-20 %, intégrant un impact tarifaire de 15-20 millions de dollars.

La croissance a été généralisée : Orthopédie +5,0 % sous-jacent, Médecine du sport & ORL +5,7 %, Gestion avancée des plaies +10,2 %. Les lancements récents de produits ont généré 75 % de la croissance du premier semestre, et le Plan en 12 points a réduit les stocks de 69 millions de dollars (-46 jours de stock). La marge en orthopédie s'est améliorée de 230 points de base ; celle de la gestion avancée des plaies de 160 points de base.

Risques clés : pression VBP en Chine, marchés émergents en baisse de -0,9 % sous-jacent au premier semestre, possibles modifications de Medicare en 2026 concernant les substituts cutanés, hausse du taux d'imposition opérationnel (19,8 % contre 17,8 %) et impact tarifaire de 15-20 millions de dollars. Néanmoins, les progrès opérationnels et la solidité du bilan soutiennent la poursuite des retours de trésorerie.

Smith & Nephew (NYSE:SNN) veröffentlichte in seinem 6-K-Bericht erneut solide Zahlen.

  • Der Umsatz im zweiten Quartal 2025 stieg auf 1,553 Mrd. USD, +7,8% gemeldet (+6,7% bereinigt); der Umsatz im ersten Halbjahr erreichte 2,961 Mrd. USD, +4,7% gemeldet (+5,0% bereinigt), trotz zwei Handelstagen weniger.
  • Der Handelsgewinn im ersten Halbjahr stieg um 11,2% auf 523 Mio. USD; die Handelsmarge verbesserte sich um 100 Basispunkte auf 17,7%, während der operative Gewinn um 30,6% auf 429 Mio. USD sprang.
  • Der freie Cashflow stieg auf 244 Mio. USD (H1 2024: 39 Mio. USD) bei einer Cash-Conversion-Rate von 93%; die Nettoverschuldung/angepasstes EBITDA liegt bei 1,8×.
  • Die Zwischen-Dividende wurde um 4,2% auf 15,0 Cent je Aktie erhöht, und ein Aktienrückkaufprogramm über 500 Mio. USD für das zweite Halbjahr 2025 angekündigt.
  • Die Prognose für das Geschäftsjahr 2025 bleibt unverändert: etwa 5% bereinigtes Umsatzwachstum (5,5% gemeldet) und eine Handelsmarge von 19-20%, wobei ein Tarifbelastung von 15-20 Mio. USD berücksichtigt wird.

Das Wachstum war breit gefächert: Orthopädie +5,0% bereinigt, Sportmedizin & HNO +5,7%, Advanced Wound Management +10,2%. Jüngste Produkteinführungen generierten 75% des Wachstums im ersten Halbjahr, und der 12-Punkte-Plan reduzierte das Inventar um 69 Mio. USD (-46 Lagerhaltungstage). Die Marge in der Orthopädie verbesserte sich um 230 Basispunkte; die Marge im Advanced Wound Management um 160 Basispunkte.

Wesentliche Risiken: VBP-Druck in China, Schwäche in den Schwellenländern mit -0,9% bereinigt im ersten Halbjahr, mögliche Medicare-Änderungen 2026 für Hautersatzstoffe, höhere operative Steuerquote (19,8% vs. 17,8%) und eine Tarifbelastung von 15-20 Mio. USD. Dennoch stützen operative Fortschritte und eine starke Bilanz weiterhin die kontinuierlichen Cash-Rückflüsse.

Positive
  • None.
Negative
  • None.

Insights

TL;DR – Beats on growth, margin, cash; buyback signals confidence.

Revenue accelerated to 6.7% underlying in Q2, well ahead of the 5% full-year target, while H1 trading margin expanded 100 bps to 17.7% on manufacturing savings and portfolio rationalisation. Free cash flow quintupled to $244 m and leverage held at 1.8×, allowing a $500 m buyback atop a 4.2% dividend increase without straining covenants. Guidance of 19-20% margin implies a further 130-230 bps lift in H2, pointing to double-digit EPSA growth. For a £12 bn market-cap, the repurchase equates to ~3% of shares—an accretive deployment of excess cash. Overall, fundamentals trend positively and support multiple expansion.

TL;DR – China, reimbursement and tariff issues temper the upside.

Underlying revenue in Emerging Markets fell 0.9% and China faces ongoing VBP pressure on arthroscopy consumables, limiting Sports Med growth. CMS proposals for single-payment skin substitutes could dent Advanced Wound margins from 2026; management flags it as a likely headwind. The company also bakes in a $15-20 m tariff drag and a higher 19.8% trading-tax rate. While inventory reductions improve working-capital optics, they may be non-repeatable. Investors should watch H2 progress toward the ambitious 19-20% margin band and any escalation of Chinese pricing reforms.

Smith & Nephew (NYSE:SNN) ha registrato un altro periodo solido nel suo rapporto 6-K.

  • I ricavi del secondo trimestre 2025 sono aumentati a 1,553 miliardi di dollari, +7,8% riportato (+6,7% a parità di condizioni); i ricavi del primo semestre hanno raggiunto 2,961 miliardi di dollari, +4,7% riportato (+5,0% a parità di condizioni) nonostante due giorni di negoziazione in meno.
  • L'utile operativo del primo semestre è cresciuto dell'11,2% a 523 milioni di dollari; il margine operativo si è ampliato di 100 punti base al 17,7%, mentre l'utile operativo è salito del 30,6% a 429 milioni di dollari.
  • Il flusso di cassa libero è aumentato a 244 milioni di dollari (primo semestre 2024: 39 milioni) con un tasso di conversione in cassa del 93%; il rapporto debito netto/EBITDA rettificato è a 1,8×.
  • Il dividendo intermedio è stato incrementato del 4,2% a 15,0 centesimi per azione ed è stato annunciato un riacquisto di azioni per 500 milioni di dollari per il secondo semestre 2025.
  • Le previsioni per l'intero anno 2025 restano invariate: crescita dei ricavi sottostanti di circa il 5% (5,5% riportata) e margine operativo tra il 19% e il 20%, assorbendo un impatto tariffario di 15-20 milioni di dollari.

La crescita è stata diffusa: Ortopedia +5,0% a parità di condizioni, Medicina dello Sport & ORL +5,7%, Gestione Avanzata delle Ferite +10,2%. I recenti lanci di prodotto hanno generato il 75% della crescita del primo semestre, e il Piano 12-Punti ha ridotto l'inventario di 69 milioni di dollari (-46 giorni di scorte). Il margine dell'Ortopedia è migliorato di 230 punti base; quello della Gestione Avanzata delle Ferite di 160 punti base.

Rischi chiave: pressione sul prezzo di riferimento in Cina (VBP), mercati emergenti con un calo sottostante del -0,9% nel primo semestre, possibili modifiche a Medicare nel 2026 per i sostituti della pelle, aumento dell'aliquota fiscale operativa (19,8% vs. 17,8%) e impatto tariffario di 15-20 milioni di dollari. Tuttavia, i progressi operativi e la solidità del bilancio sostengono il continuo ritorno di cassa agli azionisti.

Smith & Nephew (NYSE:SNN) presentó otro período sólido en su informe 6-K.

  • Los ingresos del segundo trimestre de 2025 aumentaron a 1.553 millones de dólares, +7,8% reportado (+6,7% subyacente); los ingresos del primer semestre alcanzaron 2.961 millones de dólares, +4,7% reportado (+5,0% subyacente) a pesar de dos días de negociación menos.
  • El beneficio operativo del primer semestre creció un 11,2% hasta 523 millones; el margen operativo se amplió 100 puntos básicos hasta el 17,7%, mientras que el beneficio operativo aumentó un 30,6% hasta 429 millones.
  • El flujo de caja libre subió a 244 millones (primer semestre 2024: 39 millones) con una conversión de caja del 93%; la deuda neta/EBITDA ajustado se sitúa en 1,8×.
  • El dividendo intermedio aumentó un 4,2% hasta 15,0 centavos por acción y se anunció una recompra de acciones de 500 millones de dólares para el segundo semestre de 2025.
  • Las perspectivas para todo el año 2025 permanecen sin cambios: crecimiento subyacente de ingresos de alrededor del 5% (5,5% reportado) y margen operativo del 19-20%, absorbiendo un impacto arancelario de 15-20 millones de dólares.

El crecimiento fue generalizado: Ortopedia +5,0% subyacente, Medicina Deportiva & ORL +5,7%, Gestión Avanzada de Heridas +10,2%. Los recientes lanzamientos de productos generaron el 75% del crecimiento del primer semestre, y el Plan de 12 Puntos redujo el inventario en 69 millones de dólares (-46 días de inventario). El margen de Ortopedia mejoró 230 puntos básicos; el margen de Gestión Avanzada de Heridas +160 puntos básicos.

Riesgos clave: presión VBP en China, mercados emergentes con un descenso subyacente del -0,9% en el primer semestre, posibles cambios en Medicare en 2026 para sustitutos de piel, mayor tasa impositiva operativa (19,8% vs. 17,8%) e impacto arancelario de 15-20 millones de dólares. No obstante, las mejoras operativas y la fortaleza del balance respaldan la continuidad en la devolución de efectivo a los accionistas.

Smith & Nephew (NYSE:SNN)는 6-K 보고서에서 또 한 번 견고한 실적을 발표했습니다.

  • 2025년 2분기 매출은 15억 5,300만 달러로 전년 대비 7.8% 증가(기저 효과 제외 6.7% 증가); 상반기 매출은 29억 6,100만 달러로 4.7% 증가(기저 효과 제외 5.0% 증가)했으며, 거래일이 2일 줄었음에도 불구하고 성장했습니다.
  • 상반기 영업이익은 5억 2,300만 달러로 11.2% 증가했고, 영업이익률은 100bp 확대되어 17.7%를 기록했으며, 영업이익은 4억 2,900만 달러로 30.6% 급증했습니다.
  • 자유현금흐름은 2억 4,400만 달러로 급증했으며(2024년 상반기: 3,900만 달러), 현금 전환율은 93%에 달했습니다; 순부채/조정 EBITDA 비율은 1.8배입니다.
  • 중간배당금은 주당 15.0센트로 4.2% 인상되었으며, 2025년 하반기에는 5억 달러 규모의 자사주 매입이 발표되었습니다.
  • 2025년 연간 전망은 변함없으며, 기저 효과 제외 매출 성장 약 5%(보고 기준 5.5%), 19-20%의 영업이익률을 예상하며, 1,500만~2,000만 달러의 관세 영향이 반영됩니다.

성장은 전 부문에 걸쳐 나타났습니다: 정형외과 +5.0% 기저 효과 제외, 스포츠 의학 및 이비인후과 +5.7%, 첨단 상처 관리 +10.2%. 최근 출시된 제품들이 상반기 성장의 75%를 차지했으며, 12포인트 계획으로 재고가 6,900만 달러(-46일 재고일수) 감소했습니다. 정형외과 마진은 230bp 개선되었고, 첨단 상처 관리 마진은 160bp 상승했습니다.

주요 위험요인: 중국의 VBP 압력, 신흥 시장 상반기 기저 효과 제외 -0.9%, 2026년 피부 대체재 관련 Medicare 변경 가능성, 영업세율 상승(19.8% vs. 17.8%), 1,500만~2,000만 달러 관세 부담. 그럼에도 불구하고 운영 성과와 재무 건전성이 지속적인 현금 환원 기반을 뒷받침합니다.

Smith & Nephew (NYSE:SNN) a publié une nouvelle période solide dans son rapport 6-K.

  • Le chiffre d'affaires du deuxième trimestre 2025 a augmenté pour atteindre 1,553 milliard de dollars, +7,8% en données publiées (+6,7% en données sous-jacentes) ; le chiffre d'affaires du premier semestre a atteint 2,961 milliards de dollars, +4,7% en données publiées (+5,0% en données sous-jacentes) malgré deux jours de bourse en moins.
  • Le résultat opérationnel courant du premier semestre a progressé de 11,2% à 523 millions de dollars ; la marge opérationnelle s'est élargie de 100 points de base à 17,7%, tandis que le résultat opérationnel a bondi de 30,6% à 429 millions de dollars.
  • La trésorerie nette disponible a fortement augmenté à 244 millions de dollars (S1 2024 : 39 millions) avec un taux de conversion de trésorerie de 93 % ; la dette nette/EBITDA ajusté s'établit à 1,8×.
  • Le dividende intérimaire a été augmenté de 4,2 % à 15,0 cents par action et un rachat d'actions de 500 millions de dollars a été annoncé pour le second semestre 2025.
  • Les perspectives pour l'exercice 2025 restent inchangées : croissance sous-jacente du chiffre d'affaires d'environ 5 % (5,5 % en données publiées) et marge opérationnelle de 19-20 %, intégrant un impact tarifaire de 15-20 millions de dollars.

La croissance a été généralisée : Orthopédie +5,0 % sous-jacent, Médecine du sport & ORL +5,7 %, Gestion avancée des plaies +10,2 %. Les lancements récents de produits ont généré 75 % de la croissance du premier semestre, et le Plan en 12 points a réduit les stocks de 69 millions de dollars (-46 jours de stock). La marge en orthopédie s'est améliorée de 230 points de base ; celle de la gestion avancée des plaies de 160 points de base.

Risques clés : pression VBP en Chine, marchés émergents en baisse de -0,9 % sous-jacent au premier semestre, possibles modifications de Medicare en 2026 concernant les substituts cutanés, hausse du taux d'imposition opérationnel (19,8 % contre 17,8 %) et impact tarifaire de 15-20 millions de dollars. Néanmoins, les progrès opérationnels et la solidité du bilan soutiennent la poursuite des retours de trésorerie.

Smith & Nephew (NYSE:SNN) veröffentlichte in seinem 6-K-Bericht erneut solide Zahlen.

  • Der Umsatz im zweiten Quartal 2025 stieg auf 1,553 Mrd. USD, +7,8% gemeldet (+6,7% bereinigt); der Umsatz im ersten Halbjahr erreichte 2,961 Mrd. USD, +4,7% gemeldet (+5,0% bereinigt), trotz zwei Handelstagen weniger.
  • Der Handelsgewinn im ersten Halbjahr stieg um 11,2% auf 523 Mio. USD; die Handelsmarge verbesserte sich um 100 Basispunkte auf 17,7%, während der operative Gewinn um 30,6% auf 429 Mio. USD sprang.
  • Der freie Cashflow stieg auf 244 Mio. USD (H1 2024: 39 Mio. USD) bei einer Cash-Conversion-Rate von 93%; die Nettoverschuldung/angepasstes EBITDA liegt bei 1,8×.
  • Die Zwischen-Dividende wurde um 4,2% auf 15,0 Cent je Aktie erhöht, und ein Aktienrückkaufprogramm über 500 Mio. USD für das zweite Halbjahr 2025 angekündigt.
  • Die Prognose für das Geschäftsjahr 2025 bleibt unverändert: etwa 5% bereinigtes Umsatzwachstum (5,5% gemeldet) und eine Handelsmarge von 19-20%, wobei ein Tarifbelastung von 15-20 Mio. USD berücksichtigt wird.

Das Wachstum war breit gefächert: Orthopädie +5,0% bereinigt, Sportmedizin & HNO +5,7%, Advanced Wound Management +10,2%. Jüngste Produkteinführungen generierten 75% des Wachstums im ersten Halbjahr, und der 12-Punkte-Plan reduzierte das Inventar um 69 Mio. USD (-46 Lagerhaltungstage). Die Marge in der Orthopädie verbesserte sich um 230 Basispunkte; die Marge im Advanced Wound Management um 160 Basispunkte.

Wesentliche Risiken: VBP-Druck in China, Schwäche in den Schwellenländern mit -0,9% bereinigt im ersten Halbjahr, mögliche Medicare-Änderungen 2026 für Hautersatzstoffe, höhere operative Steuerquote (19,8% vs. 17,8%) und eine Tarifbelastung von 15-20 Mio. USD. Dennoch stützen operative Fortschritte und eine starke Bilanz weiterhin die kontinuierlichen Cash-Rückflüsse.

 
 

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

Commission File Number: 1-15270

For the month of August 2025

NOMURA HOLDINGS, INC.

(Translation of registrant’s name into English)

13-1, Nihonbashi 1-chome

Chuo-ku, Tokyo 103-8645

Japan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F  X    Form 40-F    

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):    

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):    

 

 
 


Information furnished on this form:

EXHIBIT

 

Exhibit Number
1.    Supplement for Financial Highlights – Three months ended June 30, 2025

The registrant hereby incorporates Exhibit 1 to this report on Form 6-K by reference (i) in the prospectus that is part of the Registration Statement on Form F-3 (Registration No. 333-283915) of the registrant, filed with the SEC on December 19, 2024 and (ii) in the prospectus that is part of the Registration Statement on Form F-3 (Registration No. 333-273353) of the registrant and of Nomura America Finance, LLC, filed with the SEC on July 20, 2023.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   NOMURA HOLDINGS, INC.
Date: August 5, 2025    By:   

/s/ Yoshifumi Kishida

      Yoshifumi Kishida
      Senior Managing Director


Presentation of Financial and Other Information

As used in this Form 6-K, references to “Nomura” are to Nomura Holdings, Inc. and its consolidated entities. References to “NHI” are to Nomura Holdings, Inc.

Unless otherwise stated, references in this Form 6-K to “yen” are to Japanese yen. Amounts shown in this Form 6-K have been rounded to the nearest indicated digit unless otherwise specified. In tables and paragraphs with rounded figures, sums may not add up due to rounding.

Except as otherwise indicated, all financial information with respect to Nomura presented in this Form 6-K is presented on an unaudited consolidated basis in accordance with U.S. generally accepted accounting principles.

Supplement for Financial Highlights—3 months ended June 30, 2025

Nomura reported net revenue of 523.3 billion yen for the 3 months ended June 30, 2025, an increase of 15.2% from the same period in the previous year. Non-interest expenses increased by 3.3% from the same period in the previous year to 363.0 billion yen. Income before income taxes was 160.3 billion yen and net income attributable to NHI shareholders was 104.6 billion yen for the 3 months ended June 30, 2025. Basic-Net income attributable to NHI shareholders per share was 35.19 yen and Diluted-Net income attributable to NHI shareholders per share was 34.04 yen. Return on shareholders’ equity was 12.0%. Return on shareholders’ equity annualized is calculated as the ratio of net income attributable to NHI shareholders to total NHI shareholders’ equity multiplied by 4 to annualize the figure.

i.) Financial Position

As of June 30, 2025, Nomura’s main balance sheet indicators were as follows:

 

   

Total assets: 58.1 trillion yen (an increase of 1.3 trillion yen compared to March 31, 2025 due mainly to an increase in Trading assets)

 

   

Total liabilities: 54.5 trillion yen (an increase of 1.3 trillion yen compared to March 31, 2025 due mainly to an increase in Trading liabilities)

 

   

Total equity: 3.6 trillion yen (an increase of 0.01 trillion yen compared to March 31, 2025 due mainly to an increase in Retained earnings)

 

   

Total NHI shareholders’ equity: 3.5 trillion yen

As of June 30, 2025, Nomura’s capital-related indicators were as follows1:

 

   

Tier 1 Capital: 3,398 billion yen (3,500 billion yen as of March 31, 2025)

 

   

Tier 2 Capital: 26.6 billion yen (0.6 billion yen as of March 31, 2025)

 

   

Total Capital: 3,425 billion yen (3,500 billion yen as of March 31, 2025)

 

   

Tier 1 Capital ratio: 14.8% (16.2% as of March 31, 2025)

 

   

Common Equity Tier 1 Capital ratio: 13.2% (14.5% as of March 31, 2025)

 

   

Consolidated Capital Adequacy ratio: 14.9% (16.2% as of March 31, 2025)

 

   

Consolidated Leverage ratio (Tier 1 capital divided by exposure (the sum of on-balance sheet exposures and off-balance sheet items)): 4.80% (5.16% as of March 31, 2025)

 

   

Risk weighted assets: 22,887 billion yen (an increase from 21,497 billion yen as of March 31, 2025 due mainly to an increase of Credit Risk)

 

1 

Ratios and figures in this paragraph represent preliminary estimates as of the date of this supplement release and may be revised upon finalization, which is currently expected to occur by the end of October 2025.

 

1


NHI has been assigned as a Final Designated Parent Company who must calculate a consolidated capital adequacy ratio according to the “Establishment of standards on sufficiency of capital stock of a final designated parent company and its subsidiary entities, etc. compared to the assets held thereby” (2010 FSA Regulatory Notice No. 130; “Capital Adequacy Notice on Final Designated Parent Company”). Since then, the Capital Adequacy Notice on Final Designated Parent Company has been revised to be in line with Basel 2.5 and Basel III.

Since its designation as a Final Designated Parent Company in April 2011, NHI has been calculating its consolidated capital adequacy ratio according to the Capital Adequacy Notice on Final Designated Parent Company and, from the end of March 2013, according to a Basel III-based consolidated capital adequacy ratio.

 

ii.)

Value at Risk

Value at risk as of June 30, 2025 was 4.5 billion yen, 18.4% increase compared to March 31, 2025. Value at risk is defined at 95% confidence level. The time horizon for our outstanding portfolio is 1 day. Inter-product price fluctuations are considered.

 

iii.)

Number of Employees

As of June 30, 2025, Nomura had 27,908 employees globally (Japan: 15,317, Europe: 3,155, Americas: 2,476, Asia and Oceania (including Powai office in India): 6,960).

 

2


The 3 months ended June 30, 2025—Business Highlights

Business Segment Information

Wealth Management

Results of operation*

 

     Billions of yen     % Change  
      For the 3 months ended         
     June 30,
2024 (A)
     June 30,
2025 (B)
    (B-A)/(A)  

Net revenue

     109.7        105.8        (3.6

Non-interest expenses

     68.5        67.0       (2.2
  

 

 

    

 

 

   

 

 

 

Income (loss) before income taxes

     41.2        38.8       (5.9
  

 

 

    

 

 

   

 

 

 

Net revenue decreased from ¥109.7 billion for the 3 months ended June 30, 2024 to ¥105.8 billion for the 3 months ended June 30, 2025 primarily due to a decrease in commissions. Non-interest expenses were ¥67.0 billion and income before income taxes was ¥38.8 billion.

 

*

We established a new Banking Division, effective April 1, 2025. Accordingly, prior period amounts have been reclassified to conform to the current year presentation.

KPIs

 

     Trillions of yen      % Change  
     March 31,
2025 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Recurring revenue assets

      23.5         24.6          4.7   
     Billions of yen      % Change  
     For the 3 months ended         
     June 30,
2024 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Net inflows of recurring revenue assets(1)

     387.9        278.9        (28.1
     Thousands      % Change  
     For the 3 months ended         
     June 30,
2024 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Flow business clients

     925        914        (1.2
     Thousands      % Change  
     March 31,
2025 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Workplace services

     3,883        3,963        2.1  
 
(1)

Net inflows of recurring revenue assets are defined and calculated by subtracting the amount of sell-offs and outflows from the amount of purchase and inflows of recurring revenue assets, and is an index used to measure the expansion of recurring revenue assets excluding changes in market value.

 

3


Investment Management

Results of operation

 

     Billions of yen      % Change  
     For the 3 months ended         
     June 30,
2024 (A)
    June 30,
2025 (B)
     (B-A)/(A)  

Net revenue

     47.7        50.6        6.1  

Non-interest expenses

     24.5       29.0        18.6  
  

 

 

   

 

 

    

 

 

 

Income (loss) before income taxes

     23.2       21.5        (7.1
  

 

 

   

 

 

    

 

 

 

Net revenue increased from ¥47.7 billion for the 3 months ended June 30, 2024 to ¥50.6 billion for the 3 months ended June 30, 2025, primarily due to an increase in Business revenue. Non-interest expenses were ¥29.0 billion and income before income taxes was ¥21.5 billion.

The breakdown of net revenue for Investment Management is as follows:

 

     Billions of yen      % Change  
     For the year ended         
     March 31,
2024 (A)
     March 31,
2025 (B)
     (B-A)/(A)  

Business revenue(1)

     39.1        40.7        4.1  

Investment gain/ loss(2)

     8.6        9.9        15.1  
  

 

 

    

 

 

    

 

 

 

Net revenue

     47.7        50.6        6.1  
  

 

 

    

 

 

    

 

 

 
 
(1)

Consists of divisional revenue, other than investment gain/loss, including revenue generated by our asset management business (excluding gains and losses related to our investment in American Century Investments), revenues generated by Nomura Babcock & Brown Co., Ltd.’s aircraft leasing related businesses and management fee revenues generated from our private equity and other investment businesses.

 

(2)

Consists of divisional revenue attributable to investments (including fair value fluctuations, funding cost and dividends), including gains and losses related to our investment in American Century Investments, our investments held in our private equity and other investment businesses.

KPIs

 

     Trillions of yen      % Change  
     March 31,
2025 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Asset Under Management

      89.3         94.3          5.6  
     Billions of yen      % Change  
     For the 3 months ended         
     June 30,
2024 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Net inflows

     951        108        (88.6

 

4


Wholesale

Results of operation

 

     Billions of yen      % Change  
     For the 3 months ended      (B-A)/(A)  
     June 30,
2024 (A)
     June 30,
2025 (B)
 

Net revenue

     244.8        261.1        6.6  

Non-interest expenses

     223.7        219.2        (2.0
  

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

     21.1        41.9        98.4  
  

 

 

    

 

 

    

 

 

 

The breakdown of net revenue for Wholesale is as follows:

 

     Billions of yen      % Change  
     For the 3 months ended      (B-A)/(A)  
     June 30,
2024 (A)
     June 30,
2025 (B)
 

Fixed Income

     125.6        124.9        (0.6

Equities

     82.0        98.3        19.9  

Global Markets

     207.7        223.2        7.5  

Investment Banking

     37.2        37.9        1.9  
  

 

 

    

 

 

    

 

 

 

Net revenue

     244.8        261.1        6.6  
  

 

 

    

 

 

    

 

 

 

Global Markets net revenue was ¥223.2 billion. Fixed Income net revenue decreased from ¥125.6 billion for the 3 months ended June 30, 2024 to ¥124.9 billion for the 3 months ended June 30, 2025 because of a slowdown from the same period of last year’s strong performance in spread products. Equities net revenue increased from ¥82.0 billion for the 3 months ended June 30, 2024 to ¥98.3 billion for the 3 months ended June 30, 2025 due to strong performances in equity products. Investment banking net revenue was ¥37.9 billion.

KPIs

 

     Three months ended  
     June 30,  

Cost-to-income ratio

  

2024/25

     91

2025/26

     84

Revenue/modified RWA

  

2024/25

     7.3

2025/26

     6.9

 

5


Banking

Results of operation*

 

     Billions of yen      % Change  
     For the 3 months ended      (B-A)/(A)  
     June 30,
2024 (A)
     June 30,
2025 (B)
 

Net revenue

      11.2         12.8         14.4  

Non-interest expenses

     7.2        9.2        28.2  
  

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

     4.0        3.6        (10.4
  

 

 

    

 

 

    

 

 

 

Net revenue increased from ¥11.2 billion for the 3 months ended June 30, 2024 to ¥12.8 billion for the 3 months ended June 30, 2025. Non-interest expenses were ¥9.2 billion and income before income taxes was ¥3.6 billion.

 

*

We established a new Banking Division, effective April 1, 2025. Accordingly, prior period amounts have been reclassified to conform to the current year presentation.

KPIs

 

     Billions of yen      % Change  
     March 31,
2025 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Loan Outstanding (The Nomura Trust and Banking Co., Ltd.)(1)

     1,044           1,069           2.4  
     Trillions of yen      % Change  
     March 31,
2025 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Investment Trust balance (The Nomura Trust and Banking Co., Ltd.)(2)

     40.5        40.0        (1.2
     Billions of dollars      % Change  
     March 31,
2025 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Assets under administration (Nomura Bank (Luxembourg) S.A.)(3)

     55.6        59.3        6.7  
 
(1)

The total balance of loans conducted by The Nomura Trust and Banking Co., Ltd. (“NTB”), such as private banking loans and the “Nomura Web Loan” securities-backed loan product, corresponds to the figure for “Loans” disclosed on the asset side of NTB’s standalone balance sheet. Such figure is disclosed on the basis of regulatory standards based on accounting principles generally accepted in Japan and does not necessarily correspond to “Loans receivable” as disclosed by NHI on its consolidated balance sheet, which is prepared on the basis of accounting principles generally accepted in the United States.

 

(2)

The asset balance of investment trusts entrusted to NTB, calculated as the total net asset value of each fund as of its respective most recent fiscal period end. Such fiscal period end may not align with the date shown, and, for funds with only annual or semi-annual accounting, such period-end may not have occurred, and the amount may not have been updated, during the relevant quarter. The amount shown corresponds to the figure for “Investment Trusts” disclosed on the liability side of NTB’s standalone Statement of Trust Account. Such figure, which is disclosed on the basis of Japanese regulatory standards, is not included in NHI’s consolidated balance sheet.

 

(3)

The total asset amount of each investment trust for which Nomura Bank (Luxembourg) S.A. is responsible for calculating the net asset value, accounting treatment, order processing, nominee management, and creating preparation of various reports.

Other Operating Results*

 

     Billions of yen      % Change  
     For the 3 months ended         
     June 30,
2024 (A)
     June 30,
2025 (B)
     (B-A)/(A)  

Net revenue

      39.7         93.2        134.4   

Non-interest expenses

     27.6        38.6        39.8  
  

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

     12.2        54.6        349.1  
  

 

 

    

 

 

    

 

 

 

Net revenue was 93.2 billion yen, primarily due to profits related to the sale of land and buildings located in Takanawa 2-chome, Minato-ku, Tokyo, recorded in April 2025. Income before income taxes was 54.6 billion yen.

 

*

We established a new Banking Division, effective April 1, 2025. Accordingly, prior period amounts have been reclassified to conform to the current year presentation.

 

6


Segment Information—Operating Segment

The following table shows quarterly business segment information and reconciliation items to the consolidated statements of income.

 

     Millions of yen     % Change  
      For the 3 months ended      (B-A)/(A)  
     June 30,
2024 (A)
     June 30,
2025 (B)
 

Net revenue

       

Business segment information:

       

Wealth Management

     109,716        105,796       (3.6

Investment Management

     47,670        50,574       6.1  

Wholesale

     244,846        261,072       6.6  

Banking

     11,232        12,845       14.4  
  

 

 

    

 

 

   

 

 

 

Subtotal

     413,464        430,287       4.1  

Other

     39,739        93,160       134.4  
  

 

 

    

 

 

   

 

 

 

Net revenue

     453,203        523,447       15.5  
  

 

 

    

 

 

   

 

 

 

Reconciliation items:

       

Unrealized gain (loss) on investments in equity securities held for operating purposes

     1,239        (132     —   
  

 

 

    

 

 

   

 

 

 

Net revenue

     454,442        523,315       15.2  
  

 

 

    

 

 

   

 

 

 

Non-interest expenses

       

Business segment information:

       

Wealth Management

     68,517        67,041       (2.2

Investment Management

     24,491        29,047       18.6  

Wholesale

     223,725        219,164       (2.0

Banking

     7,200        9,231       28.2  
  

 

 

    

 

 

   

 

 

 

Subtotal

     323,933        324,483       0.2  

Other

     27,578        38,550       39.8  
  

 

 

    

 

 

   

 

 

 

Non-interest expenses

     351,511        363,033       3.3  
  

 

 

    

 

 

   

 

 

 

Reconciliation items:

       

Unrealized gain (loss) on investments in equity securities held for operating purposes

     —         —        —   
  

 

 

    

 

 

   

 

 

 

Non-interest expenses

     351,511        363,033       3.3  
  

 

 

    

 

 

   

 

 

 

Income (loss) before income taxes

       

Business segment information:

       

Wealth Management

     41,199        38,755       (5.9

Investment Management

     23,179        21,527       (7.1

Wholesale

     21,121        41,908       98.4  

Banking

     4,032        3,614       (10.4
  

 

 

    

 

 

   

 

 

 

Subtotal

     89,531        105,804       18.2  

Other*

     12,161        54,610       349.1  
  

 

 

    

 

 

   

 

 

 

Income (loss) before income taxes

     101,692        160,414       57.7  
  

 

 

    

 

 

   

 

 

 

Reconciliation items:

       

Unrealized gain (loss) on investments in equity securities held for operating purposes

     1,239        (132     —   
  

 

 

    

 

 

   

 

 

 

Income (loss) before income taxes

     102,931        160,282       55.7  
  

 

 

    

 

 

   

 

 

 

* Major components

Transactions between operating segments are recorded within segment results on commercial terms and conditions, and are eliminated in “Other.”

 

7


The following table presents the major components of income (loss) before income taxes in “Other.”

 

     Millions of yen     % Change  
     For the 3 months ended     (B-A)/(A)  
     June 30,
2024 (A)
    June 30,
2025 (B)
 

Net gain (loss) related to economic hedging transactions

     (2,853     1,067       —   

Realized gain (loss) on investments in equity securities held for operating purposes

     —        5       —   

Equity in earnings of affiliates

     14,800       12,321       (16.8

Corporate items

     5,519       (11,637     —   

Other

     (5,305     52,854       —   
  

 

 

   

 

 

   

 

 

 

Total

     12,161       54,610       349.1  
  

 

 

   

 

 

   

 

 

 

Note) Prior period amounts have been reclassified to conform to the current year presentation.

Disclaimers

 

   

This document is produced by Nomura. Copyright 2025 Nomura Holdings, Inc. All rights reserved.

 

   

Nothing in this document shall be considered as an offer to sell or solicitation of an offer to buy any security, commodity or other instrument, including securities issued by Nomura or any affiliate thereof. Offers to sell, sales, solicitations to buy, or purchases of any securities issued by Nomura or any affiliate thereof may only be made or entered into pursuant to appropriate offering materials or a prospectus prepared and distributed according to the laws, regulations, rules and market practices of the jurisdictions in which such offers or sales may be made.

 

   

No part of this document shall be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of Nomura.

 

   

The information and opinions contained in this document have been obtained from sources believed to be reliable, but no representations or warranty, express or implied, are made that such information is accurate or complete and no responsibility or liability can be accepted by Nomura for errors or omissions or for any losses arising from the use of this information.

 

   

This document contains statements that may constitute, and from time to time our management may make “forward-looking statements” within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. Any such statements must be read in the context of the offering materials pursuant to which any securities may be offered or sold in the United States. These forward-looking statements are not historical facts but instead represent only Nomura’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside Nomura’s control. Important factors that could cause actual results to differ from those in specific forward-looking statements include, without limitation, economic and market conditions, political events and investor sentiments, liquidity of secondary markets, level and volatility of interest rates, currency exchange rates, security valuations, competitive conditions and size, and the number and timing of transactions.

 

   

The review of the consolidated financial statements for the three-month period ended June 30, 2025 has not been completed by the independent auditors as of the date of this supplement. As a result of such review, certain of the information set forth herein may be materially revised. Nomura intends to disclose its reviewed consolidated financial statements in August 7, 2025.

 

   

This document should be read together with and is qualified in its entirety by reference to Nomura’s Annual Report on Form 20-F for the year ended March 31, 2025.

 

8

Nomura Hldgs

NYSE:NMR

NMR Rankings

NMR Latest News

NMR Latest SEC Filings

NMR Stock Data

19.89B
2.95B
2.49%
0.06%
Capital Markets
Financial Services
Link
Japan
Tokyo